Cost-Effectiveness of a Community Pharmacist-Led Sleep Apnea Screening Program - A Markov Model

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Perraudin, Clémence ^a,b   Le Vaillant, Marc ^b   Pelletier Fleury, Nathalie ^b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b EHESS Sciences   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTIC METHOD; ARTICLE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; HEALTH CARE COST; HEALTH INSURANCE; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; MARKOV MODEL; MASS SCREENING; PHARMACIST; PRIMARY MEDICAL CARE; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SLEEP DISORDERED BREATHING; COST; ECONOMIC MODEL; ECONOMICS; MALE; MARKOV CHAIN; MIDDLE AGED; PHARMACY; PRIMARY HEALTH CARE; SLEEP APNEA SYNDROMES;

COMMUNITY PHARMACY SERVICES; COSTS AND COST ANALYSIS; HUMANS; MALE; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; MODELS, ECONOMIC; PRIMARY HEALTH CARE; QUALITY OF LIFE; SLEEP APNEA SYNDROMES;

EID: 84879260974     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063894     Document Type: Article

References (39)

1. Young T, Peppard PE, Gottlieb DJ, (2002) Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 65(9): 1217-39.
2. Meslier N, Vol S, Balkau B, Gagnadoux F, Cailleau M, et al. (2007) Prevalence of the symptoms of obstructive sleep apnoea. Study in a French, middle-aged population. Rev Mal Respir 24: 305-13.
3. Fuhrman C, Fleury B, Nguyen XL, Delmas MC, (2012) Symptoms of sleep apnea syndrome: high prevalence and underdiagnosis in the French population. Sleep Medicine 13(7): 852-8.
4. Giles TL, Lasserson TJ, Smith BH, White J, Wright J, et al. (2006) Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev 19(3): CD001106.
5. Smith R, Ronald J, Delaive K, Walid R, Manfreda J, et al. (2002) What are obstructive sleep apnea patients being treated for prior to this diagnosis? Chest 121(1): 164-72.
6. Tregear S, Reston J, Schoelles K, Phillips B, (2010) Continuous positive airway pressure reduces risk of motor vehicle crash among drivers with obstructive sleep apnea: systematic review and meta-analysis. Sleep 33(10): 373-80.
7. Lindberg E, Carter N, Gislason T, Janson C, (2001) Role of snoring and daytime sleepiness in occupational accidents. Am J Respir Crit Care Med 164(11): 2031-5.
8. Ministère de la Santé et des Sports. Rapport sur le thème du sommeil22006.
9. Mold JW, Quattlebaum C, Schinnerer E, Boeckman L, Orr W, et al. (2011) Identification by primary care clinicians of patients with obstructive sleep apnea: a practice-based research network (PBRN) study. J Am Board Fam Med 24(2): 138-45.
10. Chapman JL, Zechel A, Carter YH, Abbott S, (2004) Systematic review of recent innovations in service provision to improve access to primary care. Brit J Gen Pract54: 374-81.
11. Manolakis PG, Skelton JB, (2010) Pharmacists' contributions to primary care in the United States Collaborating to address unmet patient care needs: the emerging role for pharmacists to address the shortage of primary care providers. Am J Pharm Educ 74(10): S7.
12. Anderson C, (2000) Health promotion in community pharmacy: the UK situation. Patient Educ Couns 39(2-3): 285-91.
13. Santschi V, Chiolero A, Burnand B, Colosimo AL, Paradis G, (2011) Impact of pharmacist care in the management of cardiovascular disease factors: a systematic review and meta-analysis of randomized trials. Arc Intern Med 171: 1441-53.
14. Yuksel N, Majumdar SR, Biggs C, Tsuyuki RT, (2010) Community pharmacist-initiated screening program for osteoporosis: randomized controlled trial. Osteoporos Int 21(3): 391-8.
15. Netzer NC, Riccardo AS, Netzer CM, Clark K, Strohl KP, (1999) Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med 131(7): 485-91.
16. Johns MW, (1992) Reliability and factor analysis of the Epworth Sleepiness Scale. Sleep 15(4): 376-81.
17. Deutsch PA, Simmons MS, Wallace JM, (2006) Cost-effectiveness of split-night polysomnography and home studies in the evaluation of obstructive sleep apnea syndrome. J Clin Sleep Med 2(2): 145-53.
18. Dingli K, Coleman EL, Vennelle M, Finch SP, Wraith PK, et al. (2003) Evaluation of a portable device for diagnosingthe sleep apnoea/hypopnoea syndrome. Eur Respir J 21: 253-9.
19. Pietzsch JB, Garner A, Cipriano LA, Linehan JH, (2011) An integrated health-economic analysis of diagnosis and therapeutic strategies in the treatment of moderate to severe obstructive sleep apnea. Sleep 34(6): 695-709.
20. National Institute of Demographic Studies (2011) French Life Tables, 2007-2009.
21. Marin JM, Carrizo SJ, Vicente E, Agusti AG, (2005) Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnea with or without treatment with continuous positive airway pressure: an observational study. Lancet 365: 1046-53.
22. Engleman HM, Wild MR, (2003) Improving CPAP use by patients with the sleep apnoea/hypopnoea syndrome (SAHS). Sleep Med Rev 7(1): 81-99.
23. Gold MR, Siegel JE, Russell LB, Weinstein MC (1996) Cost-effectiveness in health and medicine. New York: Oxford University Press Inc. 448 p.
24. Toussigant P, Cosio MG, Levy RD, Groome PA, (1994) Quality adjusted life years added by treatment of obstructive sleep apnea. Sleep 17(1): 52-60.
25. Chakravorty I, Cayton RM, Szczepura A, (2002) Health utilities in evaluating intervention in the sleep apnoea/hypopnoea syndrome. Eur Respir J20: 1233-8.
26. Chervin RD, Murman DL, Malow BA, Totten V, (1999) Cost-utility of three approaches to the diagnosis of sleep apnea: polysomnography, home testing, and empirical therapy. Ann Inten Med 130: 496-505.
27. Mar J, Rueda JR, Duran-Cantolla J, Schechter C, Chilcott J, (2003) The cost-effectiveness of nCPAP treatment in patients with moderate to severe obstructive sleep apnoea. Eur Respir J 21: 515-22.
28. Bahammam A, Delaive K, Ronald J, Manfreda J, Roos L, et al. (1999) Health care utilization in males with obstructive sleep apnea syndrome two years after diagnosis and treatment. Sleep 22(6): 740-7.
29. Albarrak M, Banno K, Sabbagh AA, Delaive K, Walld R, et al. (2005) Utilization of healthcare resources in obstructive sleep apnea syndrome: a 5-year follow-up study in men using CPAP. Sleep 28(10): 1306-11.
30. Jennum P, Kjellberg J, (2011) Health, social and economical consequences of sleep-disordered breathing: a controlled national study. Thorax 66: 560-6.
31. Wirrmann V, Rodenstein D, (2004) Health care costs and the sleep apnea syndrome. Sleep Med Rev 8: 269-79.
32. Christensen DB, Farris KB, (2006) Pharmaceutical care in community pharmacies: practice and research in the US. Ann Pharmacother 40: 1400-6.
33. Noyce PR, (2007) Providing patient care through community pharmacies in the UK: policy, practice, and research. Ann Pharmacother 41: 861-8.
34. Blenkinsopp A, Anderson C, Armstrong M, (2003) Systematic review of the effectiveness of community pharmacy-based interventions to reduce risk behaviours and risk factors for coronary heart disease. J Public Health 25(2): 144-53.
35. Koshman SL, Charrois TL, Simpson SH, McAlister FA, Tsuyuki RT, (2008) Pharmacist care of patients with heart failure-A systematic review of randomized trials. Arch Intern Med 168(7): 687-94.
36. Hersberger KE, Renggli VP, Nirkko AC, Mathis J, Schwegler K, et al. (2006) Screening for sleep disorders in community pharmacies-evaluation of a campaign in Switzerland. J Clin Pharm Ther 31(1): 35-41.
37. Tran A, Fuller JM, Wong KK, Krass I, Grunstein R, et al. (2009) The development of a sleep disorder screening program in Australian community pharmacies. Pharm World Sci 31(4): 473-80.
38. Fuller JM, Wong KK, Krass I, Grunstein R, Saini B, (2011) Sleep disorders screening, sleep health awareness, and patient follow-up by community pharmacists in Australia. Patient Educ Couns 83(3): 325-35.
39. Jenkinson C, Stradiing, Petersen S, (1998) How should we evaluate health status? A comparison of three methods in patients presenting with obstructive sleep apnea. Quality of Life 7: 95-100.